NCT00635960View on ClinicalTrials.gov

Growth Hormone in Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

May 31, 2010

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Growth Hormone (Somatropin)

The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.

DRUG

Placebo

Same as for Growth hormone group

Trial Locations (2)

80131

Diparimento di Scienze Neurologiche, Naples

Istituto Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Naples

All Listed Sponsors
collaborator

Istituto Biostrutture e Immagini, CNR Naples

UNKNOWN

collaborator

Agenzia Italiana del Farmaco

OTHER_GOV

lead

Federico II University

OTHER

NCT00635960 - Growth Hormone in Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter